 I. To estimate the proportion of patients who survive progression-free for at least 6 months and the proportion of patients who have objective tumor response complete or partial in patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, treated with dalantercept. 